Singapore, April 8 -- BioDuro is expanding its global contract research, development and manufacturing organisation (CRDMO) network with the opening of a new drug substance R&D and manufacturing campus in Bengbu, China.

Additionally, high-potency labs and peptide scale-up synthesis facilities are being added to two Shanghai campuses. These developments significantly increase the company's capacity and capabilities to meet the growing demand for scalable and integrated solutions for small molecules, peptides, and complex conjugated drugs in the biopharmaceutical industry.

The newly established Bengbu campus, set to begin operations in September 2025, will strengthen drug substance manufacturing capabilities, particularly for large-scale ...